SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of REGENXBIO Inc. Securities and Sets a Lead Plaintiff Deadline of April 14, 2026

Core Viewpoint - A class action lawsuit has been initiated against REGENXBIO Inc. due to alleged misrepresentations regarding its gene therapy product RGX-111, which has faced regulatory challenges following the discovery of a tumor in a trial participant [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Andre Kuik v. REGENXBIO Inc., was filed in the United States District Court for the District of Maryland [1]. - The class action includes all individuals or entities that purchased REGENXBIO securities between February 9, 2022, and January 27, 2026 [1]. Group 2: Product and Trial Information - REGENXBIO's RGX-111 is a one-time gene therapy aimed at treating severe Mucopolysaccharidosis Type I, also known as Hurler syndrome [4]. - The company had previously made positive assertions regarding RGX-111's trial success based on favorable biomarker and safety data from an ongoing Phase I/II study [4]. Group 3: Stock Price Impact - Following the announcement of a clinical hold by the FDA due to the discovery of an intraventricular CNS tumor in a trial participant, REGENXBIO's stock price dropped from $13.41 to $11.01 per share, marking a decline of 17.8% in one day [5]. Group 4: Legal Representation - Levi & Korsinsky, LLP is representing the investors and has a history of securing significant compensation for shareholders in similar cases [6][7]. - Investors are encouraged to step forward before the April 14, 2026 deadline to be considered for lead plaintiff status [6].